Research Article
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
Table 3
BMD in patients treated with Dmab (BP-naïve and BP-prior) and BP treated patients not switched to Dmab (control group).
| | | Basal | 12 m | Change (%) |
| | BP-naïve | | | | | LS BMD (g/cm2) | 0.866 ± 0.017 | 0.912 ± 0.018# | ↑5.31 | | FN (g/cm2) | 0.780 ± 0.017 | 0.811 ± 0.018# | ↑3.97 | | TH (g/cm2) | 0.749 ± 0.015 | 0.772 ± 0.014# | ↑3.07 |
| | BP-prior | | | | | LS BMD (g/cm2) | 0.861 ± 0.008 | 0.908 ± 0.008 | ↑5.46 | | FN (g/cm2) | 0.735 ± 0.008 | 0.766 ± 0.009 | ↑4.22 | | TH (g/cm2) | 0.736 ± 0.006 | 0.757 ± 0.007 | ↑2.85 |
| | Control group | | | | | LS BMD (g/cm2) | 0.906 ± 0.009 | 0.923 ± 0.010θ | ↑1.88% | | FN (g/cm2) | 0.745 ± 0.009 | 0.752 ± 0.008 | ns | | TH (g/cm2) | 0.756 ± 0.012 | 0.758 ± 0.013 | ns |
|
|
Significant differences with BP-naïve basal; significant differences with BP-prior basal; significant differences with control group basal.
|
